This review summarizes the current understanding of GNE myopathy mechanisms, pathology, genetics, and therapeutic strategies like sialic acid supplementation.
Answers are grounded in this paper and cite their sources.
Provides overview for clinicians managing GNE myopathy; leaves open sialic acid supplementation efficacy pending prospective trials.
GNE myopathy is an ultra-rare autosomal recessive disease, which starts as a distal muscle weakness and ultimately leads to a wheelchair bound state. Molecular research and animal modelling significantly moved forward understanding of GNE myopathy mechanisms and suggested therapeutic interventions to alleviate the symptoms. Multiple therapeutic attempts are being made to supplement sialic acid depleted in GNE myopathy muscle cells. Translational research field provided valuable knowledge through natural history studies, patient registries and clinical trial, which significantly contributed to bringing forward an era of GNE myopathy treatment. In this review, we are summarising current GNE myopathy, scientific trends and open questions, which would be of significant interest for a wide neuromuscular diseases community.
No takes yet. Share an insight, caveat, or question.
Pogoryelova et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: